Generic Name and Formulations:
Milnacipran (as HCl) 12.5mg, 25mg, 50mg, 100mg; tabs.
Indications for SAVELLA:
May take with food. Titrate dose. Day 1: 12.5mg once. Days 2–3: 12.5mg twice daily. Days 4–7: 25mg twice daily. After Day 7: 50mg twice daily (recommended dose); max 100mg twice daily. Severe renal impairment (CrCl 5–29mL/min): maintenance 25mg twice daily; max 50mg twice daily. Withdraw gradually.
<18yrs: not recommended.
Concomitant MAOIs during or within 5 days of discontinuing milnacipran. During or within 14 days of discontinuing an MAOI. Concomitant linezolid or IV methylene blue. Uncontrolled narrow-angle glaucoma.
Suicidality and antidepressant drugs.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor closely for clinical worsening or unusual changes in all patients. Monitor for serotonin syndrome; discontinue if occurs. Substantial alcohol abuse, chronic liver disease, end stage renal disease: not recommended. Hypertension. Heart disease. Arrhythmias. Monitor BP and HR prior to starting therapy and periodically thereafter; reduce dose or discontinue if elevation is sustained. Seizure disorder. Mania. Severe hepatic dysfunction. Discontinue if jaundice or liver dysfunction occurs. Moderate renal impairment. Volume depleted. Hyponatremia risk (esp. in elderly). History of dysuria. GU obstruction. Risk of bleeding. Controlled narrow-angle glaucoma. Reevaluate periodically. Write ℞ for smallest practical amount. Avoid abrupt cessation. Pregnancy (Cat.C; see full labeling for effects on fetus). Nursing mothers.
See Contraindications. Avoid IV digoxin (postural hypotension, tachycardia). Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Increased risk of bleeding with concomitant aspirin, NSAIDs, or others that affect coagulation. May antagonize certain antihypertensives (eg, clonidine). Caution with other CNS-active drugs. Arrhythmias, hypertension with epinephrine, norepinephrine.
Nausea, vomiting, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, palpitations, increased heart rate, dry mouth, hypertension; rare: GU effects in men.
Tabs—60; Titration Pack (4 week supply)—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Characteristics of Unipolar Mania, Distinct from Bipolar Disorder, Described
- Aspirin, N-Acetylcysteine Effective Adjunctive Treatments in Bipolar Depression
- Subthreshold Pediatric Bipolar Disorder Is a Significant Psychiatric Burden
- Interview-Only Version of Yale-Brown Obsessive-Compulsive Scale Effective for OCD Monitoring in Youth
- Potential Biomarker Differentiates Between Bipolar Disorder With, Without Psychosis
- Part 1: Adolescent Tech Use and Mental Health: Expert Roundtable
- Challenging Stigma: Should Psychiatrists Disclose Their Own Mental Illness?
- Social Anxiety in Schizophrenia: An Overlooked Problem
- Inflammation: Is It the Link Between Rheumatoid Arthritis and Depression?
- Childhood Physical Violence Associated With Decreased Total Cholesterol
- How the Government Shutdown Affects FDA Activities
- The Robot Will See You Now: The Increasing Role of Robotics in Psychiatric Care
- Extended-Release Naltrexone Improves Psychiatric Disorders During Addiction Therapy
- Infections, Antibiotics Associated With Subsequent Increased Risk for Mental Disorders in Youth